Abstract
Vitiligo is a chronic autoimmune depigmenting skin disease that affects 0.5-2% of the world's, and melanocyte repopulation. Nanoparticle formulations, such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles (PLGA, chitosan), liposomes, and ethosomes, have shown improved skin penetration, hair follicle targeting (melanocyte reservoir), and prolonged release of active ingredients, including tacrolimus, corticosteroids and Janus kinase (JAK) inhibitors. Novel approaches such as melanocyte growth factor-loaded nanoparticles and siRNA-nanocarriers targeting the CXCL10 chemokine demonstrate strong preclinical efficacy, and one Phase II clinical trial (NCT04501830) of topical tofacitinib-loaded nanoparticles showed 52% repigmentation at 24 weeks with low systemic exposure. But while preclinical studies show promise, no nanoparticle formulation has been approved by the FDA or EMA for vitiligo treatment, with key limitations being the lack of comparative studies with existing therapies, limited translation of chemically-induced animal models which lack chronic autoimmune memory, and absence of reliable biomarkers to predict response. Looking ahead, the future of nanomedicine for vitiligo includes personalized nanomedicine based on disease specific autoantibody signatures, microneedle patches for sustained immune regulation and combination nanovaccines (tolerogenic nanoparticles presenting melanocyte self-antigens with rapamycin) to target autoreactive T cells, potentially leading to a functional cure. Overall, nanotechnology has the potential to revolutionise vitiligo therapy but requires rigorous clinical testing, disease relevant animal models and regulatory considerations.